KYIV, Dec 11 – The German pharmaceutical company STADA, after the acquisition of the pharmaceutical business for prescription and over-the-counter products of Biopharma, the manufacturer of blood-derived products, plans to focus on expanding its product line, STADA CEO Peter Goldschmidt said.

"Our goal is to give more high quality products to Ukraine. We plan to expand the product line, create additional jobs and in the next two or three years invest about EUR5 million in production capacities," he said.